Table 2.
Comparison of clinical,laboratory parameters and treatment modalities based on mortality in children with MIS-C
| Survivors (n = 27) | Non-survivors (n = 4) | p value | |
|---|---|---|---|
| Age, Age in months, median(IQR) | 96 (60, 120) | 130.5 (72, 161) | 0.26 |
| Shock, n (%) | 14 (51.85) | 4 (100) | 0.12 |
| Gastrointestinal symptoms, n (%) | 18 (66.66) | 4 (100) | 0.29 |
| Respiratory symptoms, n (%) | 17 (62.96) | 4 (100) | 0.29 |
| Skin rash, n (%) | 17 (62.96) | 0 | 0.032 |
| Pre-existing comorbidity, n (%) | 8/27 | 4/4 | 0.189 |
| Laboratory parameters | |||
| Total leucocyte count, median (IQR) | 13,240 (7700, 20,000) | 19,685 (12,450, 27,285) | 0.51 |
| Platelet count (× 105/mm3), median (IQR) | 2.05 (1.5, 3.46) | 0.46 (0.17, 2.56) | 0.098 |
| Serum IL-6 (5.00–15.0 pg/mL), median (IQR) | 41.84 (12.9, 194) (n = 19) | 55.06 (27.06, 328.76) (n = 4) | 0.21 |
| Serum ferritin (12–300 ng/ml), median (IQR) | 309.5 (140, 720.08) | 1061 (581, 2750) | 0.045 |
| NT-ProBNP (pg/mL), median (IQR) (< 125 pg/ml) | 248.63 (24.66, 3189.7) (n = 13) | 6078.29 (1500.04, 10656.5) (n = 2) | 1.46 |
| D-dimer (ng/ml), median (IQR) (0.00–255.00 ng/ml) | 1050 (741.05, 5056) (n = 17) | 4285 (385, 14,035) (n = 4) | 0.16 |
| Immunomodulation therapy | |||
| Supportive care only (n = 5) | 5 | 0 | 0.137 |
| Only IVIG (n = 6) | 5 | 1 | |
| Only steroids (n = 5) | 4 | 1 | |
| Steroid plus tocilizumab (n = 1) | 0 | 1 | |
| IVIG plus steroids (n = 14) | 13 | 1 | |
Bold represents a statistically significant value (p ≤ 0.05)